Skip to main content
Caplight Logo









Freenome

Freenome

Public
South San Francisco, CaliforniaBiotechhttps://www.freenome.com/

Freenome is now publicly traded

The data on this page reflects Freenome's private-market history up to the point it went public, including its funding rounds, valuation, and investors.

Last Round

PIPE

Dec 5, 2025

Est. Valuation at Exit

$965M

Total Funding Raised

$1.6B

Company Overview

Freenome is a biotechnology company that develops noninvasive blood-based screening tests for early cancer detection using a multiomics platform powered by machine learning.

Sector

Biotech

Verticals

HealthTech, Life Sciences, Oncology

AI Layer

Application

Keywords

liquid biopsycolorectal cancer screeningCRC screeningmultiomicsearly cancer detectioncancer diagnosticsblood-based testbiomarker discoverymedical AIprecision medicineclinical diagnosticsnon-invasive screeningAI-driven diagnosticsbiotech

Freenome Comparables

Compare Freenome with similar companies based on industry and business-model similarity.

Freenome comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Universal Diagnostics
87%
Guardant Health
83%
Delfi Diagnostics
81%

Freenome Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
PIPEDec 5, 2025
VC RoundFeb 15, 2024
Series D ExtensionJan 11, 2022
Series DDec 7, 2021
Series CAug 26, 2020
Series B
Jul 24, 2019

Key People

Founding team and executive leadership

Aaron Elliott

Chief Executive Officer

Executive Team

Freenome Investors

Notable investors and investment history

Freenome investors
InvestorRounds
EcoR1 CapitalSeries C
Andreessen HorowitzSeries B, Series C, Series A, Seed, VC Round, Series D
S32VC Round, Series B, Series D, Series C, Series A
Soleus CapitalSeries D, Series C
Bain Capital Life SciencesVC Round, Series D, Series D Extension, PIPE, Series C
Janus Henderson GroupSeries D, Series C
RA Capital AdvisorsSeries D, VC Round

Recent news

Latest coverage and updates

  • is_developingAug 1, 2026

    Freenome is developing updated next-generation version.

  • is_developingJul 27, 2026

    Freenome was planning to develop more blood-based cancer screening tests on Jul 1st '25.

  • hiresJul 23, 2026

    Freenome Inc. hires Pia Banerjee as Vice President of Digital Health.

  • is_developingJul 23, 2026

    Freenome Holdings, Inc is developing AI-enabled multiomics platform.

  • merges_withJul 23, 2026

    Freenome Inc. merged with Perceptive Capital on Jul 16th '26.

Freenome Filings

Explore SEC and related filing metadata, where available.

Freenome filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Firmographic Details

HeadquartersSouth San Francisco, California
Employee Range316
Year Founded2014
Last FundingDec 5, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?